News
Altimmune nears a key MASH trial readout, with strong market potential and new liver and alcohol studies supporting growth.
We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. Altimmune, Inc. (NASDAQ:ALT) was one of ...
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's ...
Altimmune stock rose on Tuesday without news, possibly due to high short interest. Its new trial for Alcohol Use Disorder and ...
Q1 2025 Management View CEO Vipin Garg highlighted the imminent readout of the IMPACT Phase 2b NASH trial, stating "we are confident of achieving the trial’s key efficacy and safety objectives" and ...
Altimmune Inc. (NASDAQ:ALT) is poised for a potential breakthrough in the treatment of metabolic-associated steatohepatitis (MASH) and obesity with its lead candidate pemvidutide. With a market ...
Altimmune is developing an anti-obesity drug, Pemvidutide, that shows promising results in targeting fat mass and promoting weight loss. The obesity treatment market is expected to grow ...
Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025
GAITHERSBURG, Md., May 06, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2025 ...
Altimmune Inc. ALT shares rallied more than 40% in the extended session Thursday after the clinical-stage biopharma company said 391 people enrolled in a trial of its obesity drug pemvidutide lost ...
March 13 (Reuters) - Altimmune (ALT.O), opens new tab said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat alcohol use disorder and alcohol ...
GAITHERSBURG, Md., May 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and ...
Altimmune Inc. research and ratings by Barron's. View ALT revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results